90Y radioembolization for metastatic neuroendocrine liver tumors: Preliminary results from a multi-institutional experience

Annals of Surgery

Volumn 247, Issue 6, 2008, Pages 1029-1035

  Rhee, Thomas K ^a   Lewandowski, Robert J ^a   Liu, David M ^b   Mulcahy, Mary F ^c   Takahashi, Gary ^d   Hansen, Paul D ^e   Benson III, Al B ^c   Kennedy, Andrew S ^f   Omary, Reed A ^a,g   Salem, Riad ^a,c  

^a NORTHWESTERN UNIVERSITY   (United States)

^b SACRED HEART MEDICAL CENTER   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d PROVIDENCE ST VINCENT MEDICAL CENTER   (United States)

^e Oregon Clinic   (United States)

^f Wake Radiology Oncology   (United States)

^g Northwestern University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; GLASS; MICROSPHERE; RESIN; YTTRIUM 90;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ARTIFICIAL EMBOLISM; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; LIVER FUNCTION TEST; LIVER METASTASIS; LIVER WEIGHT; MALE; MULTICENTER STUDY; NEUROENDOCRINE TUMOR; OPEN STUDY; PRIORITY JOURNAL; RADIATION DOSE; RADIOGRAPHY; RISK ASSESSMENT; SEROLOGY; SURVIVAL; TOXICITY; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANALYSIS OF VARIANCE; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MICROSPHERES; MIDDLE AGED; NEUROENDOCRINE TUMORS; POSITRON-EMISSION TOMOGRAPHY; RADIOTHERAPY DOSAGE; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; YTTRIUM RADIOISOTOPES;

EID: 44449085489     PISSN: 00034932     EISSN: None     Source Type: Journal    
DOI: 10.1097/SLA.0b013e3181728a45     Document Type: Article

References (32)

1. Benevento A, Boni L, Frediani L, et al. Result of liver resection as treatment for metastases from noncolorectal cancer. J Surg Oncol. 2000;74:24-29.
2. Atwell TD, Charboneau JW, Que FG, et al. Treatment of neuroendocrine cancer metastatic to the liver: the role of ablative techniques. Cardiovasc Intervent Radiol. 2005;28:409-421.
3. Moertel CG. Karnofsky memorial lecture. An odyssey in the land of small tumors. J Clin Oncol. 1987;5:1502-1522.
4. Perry LJ, Stuart K, Stokes KR, et al. Hepatic arterial chemoembolization for metastatic neuroendocrine tumors. Surgery. 1994;116:1111-1116; discussion 1116-1117.
5. McEntee GP, Nagorney DM, Kvols LK, et al. Cytoreductive hepatic surgery for neuroendocrine tumors. Surgery. 1990;108:1091-1096.
6. Chamberlain MN, Gray BN, Heggie JC, et al. Hepatic metastases - a physiological approach to treatment. Br J Surg. 1983;70:596-598.
7. Bilchik AJ, Sarantou T, Foshag LJ, et al. Cryosurgical palliation of metastatic neuroendocrine tumors resistant to conventional therapy. Surgery. 1997;122:1040-1047; discussion 1047-1048.
8. Nijsen F, Rook D, Brandt C, et al. Targeting of liver tumour in rats by selective delivery of holmium-166 loaded microspheres: a biodistribution study. Eur J Nucl Med. 2001;28:743-749.
9. Berber E, Flesher N, Siperstein AE. Laparoscopic radiofrequency ablation of neuroendocrine liver metastases. World J Surg. 2002;26:985-990.
10. Moertel CG, Lefkopoulo M, Lipsitz S, et al. Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med. 1992;326:519-523.
11. Gupta S, Johnson MM, Murthy R, et al. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer. 2005;104:1590-1602.
12. Oberg K, Eriksson B. Nuclear medicine in the detection, staging and treatment of gastrointestinal carcinoid tumours. Best Pract Res Clin Endocrinol Metab. 2005;19:265-276.
13. Salem R, Lewandowski RJ, Atassi B, et al. Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere): safety, tumor response, and survival. J Vasc Interv Radiol. 2005;16:1627-1639.
14. Murthy R, Xiong H, Nunez R, et al. Yttrium 90 resin microspheres for the treatment of unresectable colorectal hepatic metastases after failure of multiple chemotherapy regimens: preliminary results. J Vasc Interv Radiol. 2005;16:937-945.
15. Kennedy AS, Coldwell D, Nutting C, et al. Resin 90Y-microsphere brachytherapy for unresectable colorectal liver metastases: modern USA experience. Int J Radiat Oncol Biol Phys. 2006;65:412-425.
16. Waldherr C, Pless M, Maecke HR, et al. Tumor response and clinical benefit in neuroendocrine tumors after 7. 4 GBq (90)Y-DOTATOC. J Nucl Med. 2002;43:610-616.
17. Virgolini I, Britton K, Buscombe J, et al. In- and Y-DOTA-lanreotide: results and implications of the MAURITIUS trial. Semin Nucl Med. 2002;32:148-155.
18. McStay MK, Maudgil D, Williams M, et al. Large-volume liver metastases from neuroendocrine tumors: hepatic intraarterial 90Y-DOTA-lanreotide as effective palliative therapy. Radiology. 2005;237:718-726.
19. Wong CY, Qing F, Savin M, et al. Reduction of metastatic load to liver after intraarterial hepatic yttrium-90 radioembolization as evaluated by [18F]fluorodeoxyglucose positron emission tomographic imaging. J Vasc Interv Radiol. 2005;16:1101-1106.
20. Salem R, Thurston KG, Carr BI, et al. Yttrium-90 microspheres: radiation therapy for unresectable liver cancer. J Vasc Interv Radiol. 2002;13:S223-229.
21. Dancey JE, Shepherd FA, Paul K, et al. Treatment of nonresectable hepatocellular carcinoma with intrahepatic 90Y-microspheres. J Nucl Med. 2000;41:1673-1681.
22. Salem R, Thurston KG. Radioembolization with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies: Part 1: technical and methodologic considerations. J Vasc Interv Radiol. 2006;17:1251-1278.
23. Lewandowski RJ, Sato KT, Atassi B, et al. Radioembolization with (90)Y microspheres: angiographic and technical considerations. Cardiovasc Intervent Radiol. 2007;30:571-592.
24. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.
25. Carty SE, Jensen RT, Norton JA. Prospective study of aggressive resection of metastatic pancreatic endocrine tumors. Surgery. 1992;112:1024-1031; discussion 1031-1022.
26. Sarmiento JM, Heywood G, Rubin J, et al. Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg. 2003;197:29-37.
27. Huang C, Huang J, Yang W, et al. [90Y glass microspheres intraradiopraxis of advanced hepatic carcinoma]. Zhonghua Wai Ke Za Zhi. 1998;36:206-208.
28. Cozzi PJ, Englund R, Morris DL. Cryotherapy treatment of patients with hepatic metastases from neuroendocrine tumors. Cancer. 1995;76:501-509.
29. Moertel CG, Johnson CM, McKusick MA, et al. The management of patients with advanced carcinoid tumors and islet cell carcinomas. Ann Intern Med. 1994;120:302-309.
30. Yao KA, Talamonti MS, Nemcek A, et al. Indications and results of liver resection and hepatic chemoembolization for metastatic gastrointestinal neuroendocrine tumors. Surgery. 2001;130:677-682; discussion 682-675.
31. Panteghini M. Aspartate aminotransferase isoenzymes. Clin Biochem. 1990;23:311-319.
32. Rej R. Aminotransferases in disease. Clin Lab Med. 1989;9:667-687.